市場調査レポート

商品コード

1803013

シラカバアレルギーの世界市場：将来予測 (2032年まで) - 製品別・治療の種類別・流通チャネル別・エンドユーザー別・地域別の分析

Birch Allergy Market Forecasts to 2032 - Global Analysis By Product (Tablets, Eye Drops, Nasal Sprays, Injections and Other Products), Treatment Type, Distribution Channel, End User and By Geography

出版日: 2025年09月07日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 619,387円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 783,562円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 947,737円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,119,375円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.25円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のシラカバアレルギー市場は2025年に4億5,270万米ドルを占め、予測期間中にCAGR 7.6％で成長し、2032年には7億5,590万米ドルに達すると予測されています。

シラカバアレルギーは、白樺の木から飛散する花粉に対する免疫系反応であり、一般的に春に発生します。くしゃみ、鼻づまり、目のかゆみ、のどの炎症などのアレルギー性鼻炎症状を引き起こします。感作された人では、免疫系がシラカバ花粉のタンパク質を有害なものと誤認し、炎症を引き起こす抗体を産生します。シラカバアレルギーはしばしば口腔アレルギー症候群（OAS）と関連しており、特定の果物、野菜、ナッツ類がシラカバ花粉タンパク質との交差反応により口や喉の不快感を引き起こします。温帯地域に多く、抗ヒスタミン薬、アレルゲン回避、長期的な症状緩和のための免疫療法によって管理することができます。

市場調査報告書によると、米国はシラカバアレルギーの最大の患者層であり、その治療の最大市場でもあります。

シラカバ花粉症有病率の上昇

シラカバ花粉アレルギーの有病率の上昇は、シラカバアレルギー市場の大幅な成長を促し、高度な診断、免疫療法、個別化治療オプションへの需要を促進しています。認知度の向上と早期発見により、製薬・バイオテクノロジー分野の技術革新が加速しています。この急増はまた、アレルゲン特異的製品への戦略的投資を促し、的を絞った治療へのアクセスを拡大しています。季節性アレルギーの罹患率が世界的に上昇する中、市場は持続的な拡大を遂げ、患者の転帰を変え、アレルギー管理のあり方を再構築する態勢が整っています。

先進治療薬の高コスト

先進治療薬の高額なコストは、シラカバアレルギー市場の大きな妨げとなり、患者のアクセスや導入率を制限しています。アレルゲン特異的免疫療法など、多くの革新的な治療法には多額の費用がかかるため、人口の大部分には手が届きません。このような経済的障壁は、全体的な治療導入率を低下させ、市場の成長を鈍化させ、治療の格差を生み出しています。その結果、コストに関する課題が、先進的なシラカバアレルギー治療の普及と利用を阻害し続けています。

医療意識の高まりと診断技術

医療に対する意識の高まりと診断法の進歩が、シラカバアレルギー市場の成長を促進しています。アレルギー疾患に対する一般市民の理解の高まりは、早期検査と積極的な管理を促進し、分子診断学の革新はシラカバ固有のアレルゲンの正確な同定を可能にしています。これにより、アレルギー専門医は免疫療法をカスタマイズできるようになり、患者の転帰が向上します。世界的に、特に都市部や新興地域で認識が広まるにつれて、的を絞った治療やアレルギーにやさしい製品への需要が急増しており、ダイナミックで患者中心の市場は大きな成長の可能性を秘めています。

規制上のハードルと断片化

規制のハードルと市場の断片化は、一貫性のない基準を作り出し、製品承認までの期間を長期化させ、メーカーのコンプライアンス・コストを増加させることで、シラカバアレルギー市場に悪影響を与えます。地域間の分断は、統一された治療プロトコルと市場アクセスを制限し、革新的な治療法の拡張性を制限します。このような規制の調和の欠如は、投資を抑制し、先進的な診断・治療ソリューションの導入を遅らせ、最終的に市場成長とシラカバアレルギーの効果的な管理オプションへの患者のアクセスを妨げています。

COVID-19の影響

COVID-19の大流行は、シラカバアレルギー市場にさまざまな影響を与えました。戸外での外出が制限されたため、花粉によるアレルギー反応は一時的に減少しました。しかし、医療サービスが中断したため、アレルギー検査や免疫療法治療が遅れました。呼吸器系の健康への関心の高まりはアレルギー管理への認識を高め、eコマースの成長はOTC抗ヒスタミン薬やアレルギー緩和製品の売上を支えました。パンデミック後は、患者の受診が増加し、治療が再開されたことが、市場の回復と長期的な成長の原動力となっています。

予測期間中、副腎皮質ステロイド薬セグメントが最大となる見込み

コルチコステロイド分野は、効果的な症状緩和と患者のアドヒアランス向上により、予測期間中最大の市場シェアを占めると予想されます。その抗炎症特性は、中等度から重度のアレルギー反応の管理に役立ち、医療負担を軽減し、QOLを向上させます。意識の高まりと、鼻腔内スプレーや吸入器などの製剤の改良により、副腎皮質ステロイドは好ましい治療選択肢になりつつあります。このセグメントの拡大は技術革新を促進し、市場価値を高め、ターゲットを絞った長期的なアレルギー管理ソリューションへのシフトを強化しています。

予測期間中、免疫療法分野のCAGRが最も高くなる見込み

免疫療法は、単に症状を緩和するのではなく、根本的な原因に対処する長期的な標的治療を提供することから、予測期間中、免疫療法分野が最も高い成長率を示すと予測されます。皮下免疫療法や舌下免疫療法の採用が増加し、患者のコンプライアンスと治療成績が向上していることが需要を押し上げています。アレルゲン特異的製剤の進歩と相まって、免疫療法の持続的なベネフィットに対する患者や医療従事者の意識の高まりが、市場の裾野を広げています。

最大のシェアを占める地域

予測期間中、診断および治療オプションの進歩により、アジア太平洋地域が最大の市場シェアを占めると予想されます。都市化の進展、環境条件の変化、花粉にさらされる機会の増加が有病率の上昇につながり、効果的な管理ソリューションへの需要が高まっています。政府の取り組み、医療インフラの改善、高度な免疫療法治療の利用可能性が、市場の拡大をさらに後押ししています。さらに、患者教育の向上と積極的な医療受診行動が、地域全体の普及率を押し上げています。

CAGRが最も高い地域：

予測期間中、北米地域は最も高いCAGRを示すと予測されます。これは、認知度の向上、早期診断、SLIT錠や生物製剤のような高度な免疫療法の採用によるものです。花粉飛散時期の長期化やアレルギー性鼻炎患者の増加に伴い、効果的な治療に対する需要が急増しています。戦略的な研究開発とデジタルヘルスツールが患者の転帰を向上させ、医療インフラの改善が市場の拡大を支えています。このような成長は技術革新を促進し、バイオテクノロジー企業に力を与え、個別化医療を推進し、北米をアレルギー管理のリーダーとして位置づけています。

無料のカスタマイズサービス

当レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域区分
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東・アフリカ

第10章主な動向

契約、事業提携・協力、合弁事業
企業合併・買収 (M&A)
新製品の発売
事業拡張
その他の主要戦略

第11章企業プロファイリング

Allergy Therapeutics Plc
Regeneron Pharmaceuticals Inc.
Desentum
HAL Allergy Group
Roxall Medizin GmbH
Worg Pharmaceuticals AG
S-TARget therapeutics GmbH
Adamis Pharmaceuticals Corporation
Merck KGaA
Stallergenes Greer plc
ALK-Abello A/S
Anergis SA
Biomay AG
Laboratorios LETI SL
Bayer AG
Johnson & Johnson
Sanofi S.A.
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd.
Roche

図表

List of Tables

Table 1 Global Birch Allergy Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 3 Global Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 4 Global Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 5 Global Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 6 Global Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 7 Global Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 8 Global Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 9 Global Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 10 Global Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 11 Global Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 12 Global Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 13 Global Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 14 Global Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 15 Global Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 16 Global Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 17 Global Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 18 Global Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 19 Global Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 20 Global Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 21 Global Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 22 Global Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 23 Global Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)
Table 24 North America Birch Allergy Market Outlook, By Country (2024-2032) ($MN)
Table 25 North America Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 26 North America Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 27 North America Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 28 North America Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 29 North America Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 30 North America Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 31 North America Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 32 North America Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 33 North America Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 34 North America Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 35 North America Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 36 North America Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 37 North America Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 38 North America Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 39 North America Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 40 North America Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 41 North America Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 42 North America Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 43 North America Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 44 North America Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 45 North America Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 46 North America Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)
Table 47 Europe Birch Allergy Market Outlook, By Country (2024-2032) ($MN)
Table 48 Europe Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 49 Europe Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 50 Europe Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 51 Europe Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 52 Europe Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 53 Europe Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 54 Europe Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 55 Europe Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 56 Europe Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 57 Europe Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 58 Europe Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 59 Europe Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 60 Europe Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 61 Europe Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 62 Europe Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 63 Europe Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 64 Europe Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 65 Europe Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 66 Europe Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 67 Europe Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 68 Europe Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 69 Europe Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)
Table 70 Asia Pacific Birch Allergy Market Outlook, By Country (2024-2032) ($MN)
Table 71 Asia Pacific Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 72 Asia Pacific Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 73 Asia Pacific Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 74 Asia Pacific Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 75 Asia Pacific Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 76 Asia Pacific Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 77 Asia Pacific Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 78 Asia Pacific Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 79 Asia Pacific Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 80 Asia Pacific Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 81 Asia Pacific Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 82 Asia Pacific Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 83 Asia Pacific Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 84 Asia Pacific Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 85 Asia Pacific Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 86 Asia Pacific Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 87 Asia Pacific Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 88 Asia Pacific Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 89 Asia Pacific Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 90 Asia Pacific Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 91 Asia Pacific Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 92 Asia Pacific Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)
Table 93 South America Birch Allergy Market Outlook, By Country (2024-2032) ($MN)
Table 94 South America Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 95 South America Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 96 South America Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 97 South America Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 98 South America Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 99 South America Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 100 South America Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 101 South America Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 102 South America Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 103 South America Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 104 South America Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 105 South America Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 106 South America Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 107 South America Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 108 South America Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 109 South America Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 110 South America Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 111 South America Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 112 South America Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 113 South America Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 114 South America Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 115 South America Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)
Table 116 Middle East & Africa Birch Allergy Market Outlook, By Country (2024-2032) ($MN)
Table 117 Middle East & Africa Birch Allergy Market Outlook, By Product (2024-2032) ($MN)
Table 118 Middle East & Africa Birch Allergy Market Outlook, By Tablets (2024-2032) ($MN)
Table 119 Middle East & Africa Birch Allergy Market Outlook, By Eye Drops (2024-2032) ($MN)
Table 120 Middle East & Africa Birch Allergy Market Outlook, By Nasal Sprays (2024-2032) ($MN)
Table 121 Middle East & Africa Birch Allergy Market Outlook, By Injections (2024-2032) ($MN)
Table 122 Middle East & Africa Birch Allergy Market Outlook, By Other Products (2024-2032) ($MN)
Table 123 Middle East & Africa Birch Allergy Market Outlook, By Treatment Type (2024-2032) ($MN)
Table 124 Middle East & Africa Birch Allergy Market Outlook, By Antihistamines (2024-2032) ($MN)
Table 125 Middle East & Africa Birch Allergy Market Outlook, By Immunotherapy (2024-2032) ($MN)
Table 126 Middle East & Africa Birch Allergy Market Outlook, By Decongestants (2024-2032) ($MN)
Table 127 Middle East & Africa Birch Allergy Market Outlook, By Corticosteroids (2024-2032) ($MN)
Table 128 Middle East & Africa Birch Allergy Market Outlook, By Other Treatment Types (2024-2032) ($MN)
Table 129 Middle East & Africa Birch Allergy Market Outlook, By Distribution Channel (2024-2032) ($MN)
Table 130 Middle East & Africa Birch Allergy Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
Table 131 Middle East & Africa Birch Allergy Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
Table 132 Middle East & Africa Birch Allergy Market Outlook, By Online Pharmacies (2024-2032) ($MN)
Table 133 Middle East & Africa Birch Allergy Market Outlook, By Other Distribution Channels (2024-2032) ($MN)
Table 134 Middle East & Africa Birch Allergy Market Outlook, By End User (2024-2032) ($MN)
Table 135 Middle East & Africa Birch Allergy Market Outlook, By Hospitals (2024-2032) ($MN)
Table 136 Middle East & Africa Birch Allergy Market Outlook, By Homecare (2024-2032) ($MN)
Table 137 Middle East & Africa Birch Allergy Market Outlook, By Clinics (2024-2032) ($MN)
Table 138 Middle East & Africa Birch Allergy Market Outlook, By Other End Users (2024-2032) ($MN)

Product Code: SMRC30539

According to Stratistics MRC, the Global Birch Allergy Market is accounted for $452.7 million in 2025 and is expected to reach $755.9 million by 2032 growing at a CAGR of 7.6% during the forecast period. Birch allergy is an immune system reaction to pollen released by birch trees, commonly occurring in spring. It triggers allergic rhinitis symptoms such as sneezing, nasal congestion, itchy eyes, and throat irritation. In sensitized individuals, the immune system mistakenly identifies birch pollen proteins as harmful, producing antibodies that cause inflammation. Birch allergy is often linked to oral allergy syndrome (OAS), where certain fruits, vegetables, or nuts cause mouth or throat discomfort due to cross-reactivity with birch pollen proteins. It is prevalent in temperate regions and can be managed through antihistamines, allergen avoidance, and immunotherapy for long-term symptom relief.

According to the market research reports, the United States has the largest patient pool for birch allergy and also represents the largest market for its treatment.

Market Dynamics:

Driver:

Rising Prevalence of Birch Pollen Allergies

The rising prevalence of birch pollen allergies is driving significant growth in the birch allergy market, fueling demand for advanced diagnostics, immunotherapies, and personalized treatment options. Increased awareness and earlier detection are accelerating innovation across pharmaceutical and biotech sectors. This surge is also prompting strategic investments in allergen-specific products and expanding access to targeted care. As seasonal allergy rates climb globally, the market is poised for sustained expansion, transforming patient outcomes and reshaping allergy management landscapes.

Restraint:

High Cost of Advanced Therapies

The high cost of advanced therapies significantly hinders the Birch Allergy Market, limiting patient accessibility and adoption rates. Many innovative treatment options, such as allergen-specific immunotherapies, involve substantial expenses, making them unaffordable for a large segment of the population. This financial barrier reduces overall treatment uptake, slows market growth, and creates disparities in care. Consequently, cost-related challenges continue to impede the widespread availability and utilization of advanced birch allergy treatments.

Opportunity:

Growing Healthcare Awareness & Diagnostics

Rising healthcare awareness and advancements in diagnostics are catalyzing growth in the birch allergy market. Increased public understanding of allergic conditions is driving early testing and proactive management, while innovations in molecular diagnostics enable precise identification of birch-specific allergens. This empowers allergists to tailor immunotherapy and enhances patient outcomes. As awareness spreads globally, especially in urban and emerging regions, demand for targeted treatments and allergy-friendly products is surging-creating a dynamic, patient-centric market with strong growth potential.

Threat:

Regulatory Hurdles & Fragmentation

Regulatory hurdles and market fragmentation negatively impact the birch allergy market by creating inconsistent standards, prolonging product approval timelines, and increasing compliance costs for manufacturers. Fragmentation across regions limits uniform treatment protocols and market access, restricting the scalability of innovative therapies. This lack of regulatory harmonization discourages investment and slows the introduction of advanced diagnostic and treatment solutions, ultimately hindering market growth and patient access to effective birch allergy management options.

Covid-19 Impact

The Covid-19 pandemic had a mixed impact on the birch allergy market. Reduced outdoor exposure during lockdowns temporarily lowered pollen-related allergic reactions. However, disrupted healthcare services delayed allergy testing and immunotherapy treatments. Increased focus on respiratory health boosted awareness of allergy management, while e-commerce growth supported sales of OTC antihistamines and allergy relief products. Post-pandemic, rising patient visits and resumed treatments are driving market recovery and long-term growth.

The corticosteroids segment is expected to be the largest during the forecast period

The corticosteroids segment is expected to account for the largest market share during the forecast period, due to effective symptom relief and improving patient adherence. Their anti-inflammatory properties help manage moderate to severe allergic reactions, reducing healthcare burden and enhancing quality of life. With rising awareness and improved formulations-such as intranasal sprays and inhalers-corticosteroids are becoming a preferred treatment option. This segment's expansion is catalyzing innovation, boosting market value, and reinforcing the shift toward targeted, long-term allergy management solutions.

The immunotherapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the immunotherapy segment is predicted to witness the highest growth rate, as it offers long-term, targeted treatment that addresses the root cause rather than just alleviating symptoms. Increasing adoption of subcutaneous and sublingual immunotherapy is enhancing patient compliance and treatment outcomes, thereby boosting demand. Growing awareness among patients and healthcare providers about the lasting benefits of immunotherapy, coupled with advancements in allergen-specific formulations, is expanding market reach.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to advancements in diagnostic and treatment options. Rising urbanization, changing environmental conditions, and growing exposure to pollen are leading to higher prevalence rates, prompting greater demand for effective management solutions. Government initiatives, improved healthcare infrastructure, and the availability of advanced immunotherapy treatments are further supporting market expansion. Additionally, increasing patient education and proactive healthcare-seeking behavior are boosting adoption rates across the region.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to rising awareness, early diagnosis, and adoption of advanced immunotherapies like SLIT tablets and biologics. With longer pollen seasons and increasing allergic rhinitis cases, demand for effective treatments is surging. Strategic R&D and digital health tools are enhancing patient outcomes, while improved healthcare infrastructure supports market expansion. This growth fosters innovation, empowers biotech players, and promotes personalized medicine, positioning North America as a leader in allergy management.

Key players in the market

Some of the key players profiled in the Birch Allergy Market include Allergy Therapeutics Plc, Regeneron Pharmaceuticals Inc., Desentum, HAL Allergy Group, Roxall Medizin GmbH, Worg Pharmaceuticals AG, S-TARget therapeutics GmbH, Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, ALK-Abello A/S, Anergis SA, Biomay AG, Laboratorios LETI SL, Bayer AG, Johnson & Johnson, Sanofi S.A., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd. and Roche.

Key Developments:

In May 2025, Johnson & Johnson MedTech has joined forces with Qure.ai under Project BreatheEZ to roll out AI-powered Incidental Pulmonary Nodule detection clinics-10 hubs and 20 spokes-across India, beginning with Thangam Cancer Centre, aiming to catch lung cancer at its most treatable stage.

In March 2025, Roche unveiled an exclusive collaboration with Zealand Pharma to co-develop and co-commercialize petrelintide, a long-acting amylin analog-alone or paired with Roche's dual GLP-1/GIP agonist CT-388-to elevate care in cardiovascular, renal, and metabolic diseases.

Products Covered:

Tablets
Eye Drops
Nasal Sprays
Injections
Other Products

Treatment Types Covered:

Antihistamines
Immunotherapy
Decongestants
Corticosteroids
Other Treatment Types

Distribution Channels Covered:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels

End Users Covered:

Hospitals
Homecare
Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Birch Allergy Market, By Product

5.1 Introduction
5.2 Tablets
5.3 Eye Drops
5.4 Nasal Sprays
5.5 Injections
5.6 Other Products

6 Global Birch Allergy Market, By Treatment Type

6.1 Introduction
6.2 Antihistamines
6.3 Immunotherapy
6.4 Decongestants
6.5 Corticosteroids
6.6 Other Treatment Types

7 Global Birch Allergy Market, By Distribution Channel

7.1 Introduction
7.2 Hospital Pharmacies
7.3 Retail Pharmacies
7.4 Online Pharmacies
7.5 Other Distribution Channels

8 Global Birch Allergy Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Homecare
8.4 Clinics
8.5 Other End Users

9 Global Birch Allergy Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Allergy Therapeutics Plc
11.2 Regeneron Pharmaceuticals Inc.
11.3 Desentum
11.4 HAL Allergy Group
11.5 Roxall Medizin GmbH
11.6 Worg Pharmaceuticals AG
11.7 S-TARget therapeutics GmbH
11.8 Adamis Pharmaceuticals Corporation
11.9 Merck KGaA
11.10 Stallergenes Greer plc
11.11 ALK-Abello A/S
11.12 Anergis SA
11.13 Biomay AG
11.14 Laboratorios LETI SL
11.15 Bayer AG
11.16 Johnson & Johnson
11.17 Sanofi S.A.
11.18 GlaxoSmithKline plc
11.19 Teva Pharmaceutical Industries Ltd.
11.20 Roche

シラカバアレルギーの世界市場：将来予測 (2032年まで) - 製品別・治療の種類別・流通チャネル別・エンドユーザー別・地域別の分析

Birch Allergy Market Forecasts to 2032 - Global Analysis By Product (Tablets, Eye Drops, Nasal Sprays, Injections and Other Products), Treatment Type, Distribution Channel, End User and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

当レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序論

第3章 市場動向の分析

第4章 ポーターのファイブフォース分析

第5章 世界のシラカバアレルギー市場：製品別

第6章 世界のシラカバアレルギー市場：治療の種類別

第7章 世界のシラカバアレルギー市場：流通チャネル別

第8章 世界のシラカバアレルギー市場：エンドユーザー別

第9章 世界のシラカバアレルギー市場：地域別

第10章 主な動向

第11章 企業プロファイリング